01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
02 août 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
06 juil. 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
25 mai 2021 08h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
14 mai 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Prices Public Offering of Common Stock
13 mai 2021 22h39 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
11 mai 2021 16h22 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
11 mai 2021 08h00 HE | Praxis Precision Medicines, Inc.
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
30 avr. 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
29 avr. 2021 08h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
15 avr. 2021 16h05 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...